Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORAb-202 versus investigator's choice chemotherapy in platinum-resistant high-grade serous ovarian, primary peritoneal, or fallopian tube cancer
2021-004807-42Phase 2Active
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of farletuzumab ecteribulin in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Objective response rate. Started Oct 2022; status: active.
02
Drugs
farletuzumab ecteribulin
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on 2021-004807-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004807-42.